The proposed HHS Notice of Benefit and Payment Parameters for 2018 indicates CMS is focusing on refining the risk adjustment model to better compensate plans.
On August 29, CMS released the proposed rule for the HHS Notice of Benefit and Payment
Parameters for 2018. The rule includes payment parameters and provisions related to:
CarpenterIt also includes guidance related to qualified health plans, network adequacy, and the medical loss ratio program.
Related: 4 ways to improve ACA risk-adjustment model
To help readers understand more about the rule and the biggest impacts, we asked Elizabeth Carpenter, senior vice president of Avalere Health, a Washington, D.C., based healthcare consulting firm, to weigh in.
Managed Healthcare Executive: When reviewing the proposed rule, what three elements/changes included do you think will have the biggest impact on the industry?
Carpenter: The rules show a clear focus by the administration on refining the risk adjustment model to better predict risk and, in turn, better compensate plans. The three highest impact changes would include:
Managed Healthcare Executive:How will these changes impact industry the health insurance exchanges and the plans offering coverage through the exchanges?
Carpenter: The changes are reflective of some issuer concerns with the accuracy of the current risk model and the risk pool overall. Generally, risk mitigation programs that compensate plans appropriately will help stabilize the market, which is also good for consumers.
Managed Healthcare Executive:Could the proposed rules make it easier for insurers to succeed in offering exchange plans?
Carpenter: The rule definitely focuses on providing stability and predictability for the exchange market. However, additional changes are likely necessary to restore confidence in the market and grow carrier participation and enrollment long-term. For example, further changes may be necessary related to risk adjustm\ent. The current zero sum nature of the risk adjustment transfer formula is complex and difficult for plans to predict. Also, additional work may be necessary to grow enrollment, including additional plan options to attract younger individuals and new incentives for people to choose coverage.
Managed Healthcare Executive:What other key takeaways would you share with our readers?
Carpenter: Especially compared with earlier years, the rule contains relatively few consumer-oriented changes. There are no aggressive proposals around networks or non-discrimination. This focus is not surprising given the uncertainty in the current exchange market. Overall, a stable market and a choice of carriers benefits consumers. The changes proposed in the rule are in support of these goals, but additional reforms may be necessary.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
Extending the Capabilities of the EHR Through Automation
August 2nd 2023Welcome back to another episode of "Tuning In to the C-Suite," where Briana Contreras, an editor of Managed Healthcare Executive, had the pleasure of chatting with Cindy Gaines, chief clinical transformation officer at Lumeon.
Listen
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More
Drugs to Watch: Mental Health Conditions
April 11th 2024The FDA is reviewing two novel therapies: a psychedelic-assisted therapy for PTSD with a target action date of Aug. 11, 2024, and therapy for schizophrenia that does not directly block dopamine receptors with an action date of Sept. 26, 2024.
Read More